Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why ...

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

The tumor suppressor p53 is a transcription factor that controls the expression of hundreds of genes. Emerging evidence suggests that the p53-induced RNA-binding protein ZMAT3 is a key splicing ...

The pair form the developer team of the DHIL, an initiative that supports researchers with the development and dissemination of digital scholarship. Rooted in principles of accessibility and ...

CSL's R&D chief says the company's new hereditary angioedema treatment is one of only a few drugs to be built from scratch in ...